Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes Mellitus (T2DM), Type 1 ...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: Libre 3 Plus Continuous Glucose Monitor — Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
  • Device: Dexcom G7 Continuous Glucose Monitor — Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.

Primary Outcomes

  • Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system (From enrollment until follow-up telephone visit 2-3 weeks after discharge)
  • Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care (From enrollment until follow-up telephone visit 2-3 weeks after discharge)
  • Questionnaire responses regarding patient familiarity with continuous glucose monitoring (From enrollment until follow-up telephone visit 2-3 weeks after discharge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-09
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Contact Information
Study Contact:
Angel Morvant, MD
615-343-8332
angel.morvant@vumc.org
Angel Morvant, MD
(615) 343-8332
angel.morvant@vumc.org
Vanderbilt University Medical Center
Angel Morvant, MD
Vanderbilt University Medical Center
Interventions
  • Device: Libre 3 Plus Continuous Glucose Monitor — Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
  • Device: Dexcom G7 Continuous Glucose Monitor — Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: * Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC * Able to give informed consent * Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge * POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL * Need glucose readings greater than or equal to one time per day * Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone Exclusion Criteria: * Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months * Does not have smartphone compatible with Libre 3 App or Dexcom G7 App * Received chemotherapy during current hospitalization * Planning on major surgery within 10-15 days * Hemodialysis or peritoneal dialysis * Requiring vasopressors, intubation, sedation, or admission to an intensive care unit * Vitamin C use of more than 500 milligrams per day * Hydroxyurea use * Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours * Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion * Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state * Skin allergy to adhesives
Conditions Metastatic Breast Cancer (MBC)
Phase Not Applicable
Enrollment 187
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and expression of biomarkers Human Epidermal growth factor Receptor 2 (HER2), Estrogen Receptor (ER), and programmed death-ligand 1 (PD-L1) and cell free DNA/RNA (cfDNA/RNA) analysis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • The percentage of subjects for which the providers indicated positive impact of the cfDNA/RNA, CTC enumeration, and CTC expression results. (3-4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-13
Completion: 2028-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 187 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Menarini Silicon Biosystems, INC
Principal Investigators:
  • Marija Balic, MD, PhD, MBA (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Marija Balic, MD, PhD, MBA
800-533-8762
balicm@upmc.edu
Lisette Stork-Sloots
lstork@medex15.com
Marija Balic, MD, PhD, MBA
UPMC Magee Womens Hospital
Interventions
N/A
Study Locations (1 sites)
UPMC Magee Womens Hospital, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease. * HR+/HER2 negative or triple negative (TN) subjects prior to starting first line therapy or beyond in the metastatic setting. OR HER2+ subjects prior to starting second line therapy or beyond in the metastatic setting. * Subject must have the CTC HER2, ER, PD-L1, and cfDNA/RNA tests ordered during routine patient care. * Age \> 18 years. Exclusion Criteria: * Participant is pregnant. * Inability to provide blood samples based on the judgment of the treating physician.
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase NA
Enrollment 218
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Preoperative chemotherapy has been shown to be at least as effective as postoperative chemotherapy in breast cancer patients and has seen increased use over time. The decision regarding neoadjuvant treatment is complex, as various aspects need to be considered, and the patient's role in the decision-making process is central. The information provided by doctors to patients about preoperative treatment can be complicated, including details about treatment options, treatment plans, and side effects. If this information is not conveyed adequately, there is a risk of misunderstandings, which can lead to increased anxiety and stress for patients regarding their decisions. In oncology, question prompt lists (QPL) have been used as a tool to support patients by improving the information conveyed by doctors in various contexts where complex decisions need to be made. Studies have shown that QPL can facilitate better information exchange. However, their use in discussions about preoperative treatment for breast cancer patients has not been studied. Furthermore, evidence from randomized studies on the use of QPL in clinical practice is very limited. The aim of this study is to investigate whether the use of QPL during patient consultations involving discussions about neoadjuvant chemotherapy can improve information exchange in various aspects: understanding of the treatment; anxiety about the decision; participation in the decision-making process; patient-doctor communication; and decision-related conflict.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Other: Question prompt list — The question prompt list includes 12 questions related to neoadjuvant therapy. It has been developed by an expert team including breast surgeons, oncologists, nurses, and psychologists and has been refined through focus interview with patient advocates and caregivers.

Primary Outcomes

  • Concordance rate between patient and oncologist (Within five days from patient visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-01
Completion: 2027-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 218 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Örebro County
Principal Investigators:
  • Antonis Valachis, MD, PhD (PRINCIPAL_INVESTIGATOR) - Department of Oncology, Örebro University Hospital, Sweden
Contact Information
Study Contact:
Antonios Valachis, MD, PhD
+46 0196021792
antonios.valachis@regionorebrolan.se
Servah Hosseini, MD
Andreas Karakatsanis, MD, PhD
Akademiska Uppsala University Hospital
Interventions
  • Other: Question prompt list — The question prompt list includes 12 questions related to neoadjuvant therapy. It has been developed by an expert team including breast surgeons, oncologists, nurses, and psychologists and has been refined through focus interview with patient advocates and caregivers.
Study Locations (3 sites)
Akademiska Uppsala University Hospital, Uppsala, Region Uppsala Sweden
Västerås General Hospital, Västerås, Region Västmanland Sweden
Örebro University Hospital, Örebro, 70185 Sweden
Eligibility Criteria
Inclusion Criteria: * Patients with operable breast cancer eligible for systemic neoadjuvant therapy, according to current treatment guidelines. Exclusion Criteria: * Patients with locally advanced breast cancer where neoadjuvant therapy is mandatory rather than a treatment option. * Patients with cognitive impairment that are assessed from treating physician as unable to participate. * Patients who cannot speak/read neither Swedish nor English.

Forearm Immobilization in T2D

NCT06750497
Recruiting
Conditions Healthy, Type 2 Diabetes
Phase NA
Enrollment 26
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the present study is to assess the impact of short-term forearm immobilization on forearm muscle glucose uptake and amino acid net balance and kinetics in individuals with T2D compared with a control group with normoglycaemia.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Forearm immobilization — Two days of forearm immobilization

Primary Outcomes

  • Change in forearm muscle glucose uptake (From 0 to 48 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-21
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 26 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wageningen University
Contact Information
Study Contact:
Marlou Dirks, PhD
+31 317 480 100
marlou.dirks@wur.nl
Human and Animal Physiology
+31 (0)317 484 136
office.hap@wur.nl
Wageningen University and Research
Interventions
  • Behavioral: Forearm immobilization — Two days of forearm immobilization
Study Locations (1 sites)
Wageningen University and Research, Wageningen, Gelderland 6708WD Netherlands
Eligibility Criteria
Inclusion criteria * Males and females with or without diagnosed type 2 diabetes * Use lifestyle changes, metformin, gliclazide, or a combination thereof as oral glucose-lowering treatments for T2D * Aged 18-80 years at the time of signing informed consent * 18.5 ≥ BMI ≤ 35 kg·m2 Exclusion criteria * Type 1 or a genetic form of diabetes * Any diagnosed cardiovascular (heart) disease or high blood pressure (≥160 mmHg systolic and/or ≥100 mmHg diastolic) * Chronic use of any prescribed or over-the-counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) that interact with muscle substrate metabolism (e.g. selective serotonin reuptake inhibitors) * Consumption of a low-carbohydrate diet * Smoking or chewing tobacco * Known anaemia * Regular use of dietary protein and/or amino acid supplements (\>3 times per week) * Currently involved in a structured progressive resistance training program (\>3 times per week) * A personal or family history of thrombosis (clots) * Any previous motor disorders or inborn errors in muscle and/or lipid metabolism * History of kidney disease * History of liver disease * Pregnant or breastfeeding * History of any drug or alcohol abuse in the past two years * Claustrophobia * Unable to give consent
Conditions Hypertension, Essential Hypertension
Phase Not Applicable
Enrollment 2300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background: Childhood-onset essential hypertension (COEH) is high blood pressure that develops in children and teens. High blood pressure is a major risk factor for heart disease. COEH is more likely to be caused by changes in genes rather than by factors like stress or diet. Researchers want to learn more about how changes in genes relate to COEH. They hope to use that information to develop better treatments for children with high blood pressure. Objective: This natural history study will look for genes and gene changes that may lead to COEH. Eligibility: People aged 2 years and older with COEH or who had COEH when they were children. Healthy relatives of those with COEH are also needed. Design: Participants will have one clinic visit per year for up to 10 years. All participants will have a physical exam. They will provide samples of blood and urine. At their first visit, they will have a swab (like a Q-tip) rubbed between their gums and cheeks. They may agree to having a skin biopsy; a piece of skin about the size of a pencil eraser will be removed. Affected participants aged 2 to 17 years old will have additional tests: * They will have sensors placed on their skin to look at their blood vessels and see how blood is moving in their bodies. * They will lie or stand while a machine measures the amount of fat and muscle in their bodies. * They will have an ultrasound; a wand will be rubbed against their skin to take pictures of their kidneys. Other things are optional for all participants: * They may have photographs taken of their bodies. * They may have tests of their heart function. * They may have different types of imaging scans....

Design

Study type: Observational Observational model: Case Control Time perspective: Other

Primary Outcomes

  • Find all genes that cause COEH. (10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-30
Completion: 2034-12-09
Eligibility
Age: 2 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Human Genome Research Institute (NHGRI)
Principal Investigators:
  • Neil A Hanchard, M.D. (PRINCIPAL_INVESTIGATOR) - National Human Genome Research Institute (NHGRI)
Contact Information
Study Contact:
Emilyn C Banfield
(240) 328-0965
COEHstudy@nih.gov
Neil A Hanchard, M.D.
(301) 594-2151
neil.hanchard@nih.gov
NIH Clinical Center Office of Patient Recruitment (OPR)
800-411-1222
ccopr@nih.gov
National Institutes of Health Clinical Center
Interventions
N/A
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: To be eligible to participate in this study, an affected individual must meet one of the following criteria: * Age 2-12 years at time of enrollment with a BP of at least \>95th percentile or 120/80 mm Hg verified via medical record review and a willingness to provide biological samples, undergo physical exam, provide information related to family and medical history, and undergo imaging/body measurements (e.g., renal ultrasound) * Age 13-17 years at time of enrollment with a BP of at least 130/80 mm Hg verified via medical record review and a willingness to provide biological samples, undergo physical exam, provide information related to family and medical history, and undergo imaging/body measurements (e.g., renal ultrasound) * Age 18 years or more at time of enrollment with a medical history of meeting the criteria outlined in affected individual inclusion criteria 1 or 2, depending on age at diagnosis (verified via medical record review) and a willingness to provide biological samples, undergo physical exam, and provide information related to family and medical history To be eligible to participate in this study, an unaffected individual must meet all of the following criteria: * First-degree relative to a proband (first identified affected family member) in the study * Willingness to provide biological samples, undergo physical exam, and provide information related to family and medical history To be eligible to participate in this study, an individual with a candidate variant (regardless of known COEH status) must meet all of the following criteria: * History of clinical and/or research genomic interrogation * Positive genomic interrogation test result for candidate variant identified in earlier stages of study or in prior studies performed by study team * Willingness to provide information related to family and medical history, provide access to relevant medical records, undergo physical exam, and undergo imaging/body measurements (if 2-17 years of age and evidence of COEH exists) EXCLUSION CRITERIA: An affected individual who meets any of the following criteria will be excluded from participation in this study: * BMI \>95th percentile * Evidence that hypertension is secondary to a known condition (e.g., chronic kidney disease, aortopathy, sleep apnea, etc.) * Impaired decision-making capability, with or without a legally-authorized representative An unaffected individual who meets any of the following criteria will be excluded from participation in this study: * Prior or current diagnosis of COEH * Second-degree or greater relationship to proband * Impaired decision-making capability, with or without a legally-authorized representative An individual with a candidate variant (regardless of known COEH status) who meets any of the following criteria will be excluded from participation in this study: * No prior genomic interrogation findings available for the study team to review to confirm positive candidate variant status * Impaired decision-making capability, with or without a legally-authorized representative
Conditions Endometrioid Ovarian Cancer, Primary Per...
Phase PHASE1
Enrollment 50
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer. The study also aims to determine the recommended dose of the combination therapy. If a participant is a good fit for the study, and they enroll in the study, they will: * Visit the clinic often at the beginning of the study for physical exams, blood draws, vital signs, and other study and routine care procedures. After the first two months participants will visit the clinic every 28 days. * Take the study medications, Cirtuvivint and Olaparib. Participants will take Olaparib every day. Participants will either take Cirtuvivint 5 days per week or 2 days per week.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Cirtuvivint — Cirtuvivint (SM08502) is a first in class pan CDC-like kinase (CLK) and dual specificity tyrosine kinase (DYRK) inhibitor with suspected multiple anti-tumor mechanisms of action, including Wnt inhibition.
  • Drug: Olaparib — NCI Definition - A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.

Primary Outcomes

  • Determine the Safety of Combination Cirtuvivint with Olaparib (6 months)
  • Determine the recommended Phase 2 Dose of Cirtuvivint with Olaparib (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-12-08
Completion: 2030-09-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)
Principal Investigators:
  • Bradley Corr (PRINCIPAL_INVESTIGATOR) - University of Colorado, Denver
Contact Information
Study Contact:
Kailey Palmen, BA
303-724-2435
kailey.palmen@cuanschutz.edu
Evamaria Kent Bravo, MS
303-724-0131
evamaria.kentbravo@cuanschutz.edu
CU Medicine Clinics
Kailey Palmen
303-724-2435
kailey.palmen@cuanschutz.edu
Universtiy of Colorado Hospital
Interventions
  • Drug: Cirtuvivint — Cirtuvivint (SM08502) is a first in class pan CDC-like kinase (CLK) and dual specificity tyrosine kinase (DYRK) inhibitor with suspected multiple anti-tumor mechanisms of action, including Wnt inhibition.
  • Drug: Olaparib — NCI Definition - A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.
Study Locations (2 sites)
CU Medicine Clinics, Aurora, Colorado 80045 United States
Universtiy of Colorado Hospital, Aurora, Colorado 80045 United States
Eligibility Criteria
Inclusion Criteria: 1. Provision to sign and date the consent form. 2. Stated willingness to comply with all study procedures and be available for the duration of the study. 3. Woman aged ≥18 years of age 4. Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 1 or 2 5. Patients must have a confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer 6. Patients must have platinum-resistant disease defined as radiographic progression less than 6 months from last dose of most recent platinum therapy 7. Patients must have measurable disease by defined RECIST 1.1 criteria 8. Prior anticancer therapy: * Patients must have received at least one prior platinum-based chemotherapy regimen * Patients may not have received more than 3 prior lines of systemic therapy * Neoadjuvant +/- adjuvant therapies are considered 1 line of therapy * Maintenance therapy (eg, Bevacizumab, PARP inhibitors) will be considered part of preceding line of therapy (ie, not counted independently) * Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently) * Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance * Prior radiation is allowed and is not considered a line of treatment 9. Patients must have had testing for BRCA mutation (tumor or germline) and tumor HRD testing, and have been positive for one and/or the other. 10. Patients must have received a prior PARP inhibitor as either treatment or maintenance therapy 11. Patients must have adequate hematologic, liver, and kidney function as defined as: * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1500/µL) * Platelet count ≥ 100 x 109/L (100,000 µL) * Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days * Serum creatinine ≤ 1.5 x upper limit of normal (ULN) * Patients must have creatinine clearance estimated of ≥51 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test * Aspartate aminotransferase (AST)(Serum Glutamic Oxaloacetic Transaminase (SGOT)) and alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x ULN unless liver metastases are present in which case they must be ≤ 5x ULN * Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \< 3.0 x ULN) * Serum albumin ≥ 2 g/dL 12. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. 13. Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible. Exclusion Criteria: 1. Patients with clear cell, mucinous, sarcomatous, low grade/borderline, germ cell, or sex-cord stromal type ovarian tumor 2. Patients with platinum refractory disease as defined by those who have progressed during or within 4 weeks of receiving platinum-based therapy 3. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment 4. Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome/acute myeloid leukemia. 5. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to: * Uncontrolled major seizure disorder * Unstable spinal cord compression * Any psychiatric disorder that prohibits obtaining informed consent. * Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of therapy 6. Patients with clinically significant cardiac disease including, but not limited to, any of the following * Myocardial infarction ≤ 6 months prior to first dose * Uncontrolled ventricular arrhythmia, recent (within 3 months) * Superior vena cava syndrome * Unstable angina pectoris * Uncontrolled congestive heart failure (New York Heart Association \> class II) * Uncontrolled ≥ Grade 3 hypertension (per CTCAE) * Uncontrolled cardiac arrhythmias 7. Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment 8. Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C) 9. Persistent toxicities (\>/= Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia or peripheral sensory neuropathy 10. Patients with duodenal stent or other GI disorder/defect that would interfere with absorption of oral medication o Includes patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication 11. Patients with known untreated or symptomatic central nervous system (CNS) metastases 12. Prior known hypersensitivity reaction to study drugs and/or any of their excipients 13. Minor or major surgical procedure within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. 14. Inability to comply with study and follow-up procedures 15. Patients deemed otherwise clinically unfit for clinical trial per investigators discretion.
Conditions Depression, Anxiety, Stress, Positive Af...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This observational study will employ a multi-modal observation methodology, integrating data from wearable devices and smartphones to establish comprehensive digital biomarkers for identifying symptoms of mental health conditions in university students. The study aims to identify the digital behavioural markers associated with mental health conditions, develop predictive algorithms for mental health states from digital markers, and identify university students at risk for mental health conditions.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Observational — Participants will not receive any study intervention. During the six month study period, participants will complete four active assessments at Months 0, 1, 3 and 6, and data from the study-provided wearable (Fitbit Charge 6) and sensors from the participant's smartphone (through the Brightline app) will be collected passively throughout.

Primary Outcomes

  • Patient Health Questionnaire-9 (PHQ-9) (Baseline (Month 0), Interim (Month 1), Mid-point (Month 3), End-point (Month 6))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01
Completion: 2026-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanyang Technological University
Collaborators: Ministry of Health, Singapore
Principal Investigators:
  • Andy WH Khong, PhD (PRINCIPAL_INVESTIGATOR) - Nanyang Technological University
  • Andy HY Ho, PhD, EdD (PRINCIPAL_INVESTIGATOR) - Nanyang Technological University
Contact Information
Study Contact:
Zhi Wei Tan, PhD
+65 92312575
zhiwei.tan@ntu.edu.sg
Zhi Wei Tan, PhD
+65 92312575
zhiwei.tan@ntu.edu.sg
Nanyang Technological University
Andy WH Khong, PhD
Nanyang Technological University
Interventions
  • Other: Observational — Participants will not receive any study intervention. During the six month study period, participants will complete four active assessments at Months 0, 1, 3 and 6, and data from the study-provided wearable (Fitbit Charge 6) and sensors from the participant's smartphone (through the Brightline app) will be collected passively throughout.
Study Locations (1 sites)
Nanyang Technological University, Singapore, 639798 Singapore
Eligibility Criteria
Inclusion Criteria: * Be aged 18 years or older. * Be a current full-time undergraduate student. * Own a smartphone with Wi-Fi, 4G, and Bluetooth capabilities. * Possess adequate English language proficiency. * Be able to download the study apps. * Provide informed consent. Exclusion Criteria: * Are part-time students. * Have a current diagnosis of any mental health disorder or a past diagnosis with any bipolar disorder, substance use disorder, or any psychotic disorder. * Are currently undergoing mental health treatment. * Lack sufficient English proficiency. * Report suicidal ideation as indicated by Patient Health Questionnaire (PHQ-9) Item-9, "Thoughts you would be better off dead or of hurting yourself in some way". * Cannot commit to wearing a wearable device for the six-month monitoring period. * Receive special education accommodations or support from the university.
Conditions Chronic Thromboembolic Pulmonary Hyperte...
Phase PHASE4
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study was designed to investigate the safety and efficacy of replacing phosphodiesterase 5 inhibitors (PDE5i) with riociguat in patients with Chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary angioplasty (BPA) and remains symptomatic despite treatments with PDE5i.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Riociguat (Adempas) — Oral riociguat administered according to established dose-adjustment scheme. Riociguat will be administered starting at at 1mg three times per day. If patient systolic blood pressure maintains at 95mmHg or higher, the dose will be increased 0.5mg every 2 weeks up to a maximum dose 2.5mg three times per day over 8-week period

Primary Outcomes

  • Change in mean pulmonary artery pressure (mPAP) (26 weeks)
  • Change in pulmonary vascular resistance (PVR) (26 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-07-25
Completion: 2027-01-22
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Contact Information
Study Contact:
Daniel Xu Nurse
+85235051518
danielxu@cuhk.edu.hk
Daniel Xu Nurse
+85235051518
danielxu@cuhk.edu.hk
Prince of Wales Hospital
Interventions
  • Drug: Riociguat (Adempas) — Oral riociguat administered according to established dose-adjustment scheme. Riociguat will be administered starting at at 1mg three times per day. If patient systolic blood pressure maintains at 95mmHg or higher, the dose will be increased 0.5mg every 2 weeks up to a maximum dose 2.5mg three times per day over 8-week period
Study Locations (1 sites)
Prince of Wales Hospital, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: 1. Patients with established diagnosis of CTEPH who are symptomatic after Balloon pulmonary angioplasty (BPA) 2. Patients who are on stable maximally tolerated dose of sildenafil for at least 6 weeks as monotherapy, or in combination with other pulmonary hypertension specific therapies 3. WHO functional class III at screening 4. Stable dose of diuretics (if used) for at least 30 days at screening 5. No recent hospitalisation due to pulmonary hypertension or heart failure for at least 30 days Exclusion Criteria: 1. Previous treatment with riociguat other sGCs, or documented severe drug reaction or intolerance to sGCs 2. Use of nitrates or nitric oxide donors (eg, nitroglycerin, amyl nitrite, isosorbide dinitrate etc) by any administration routes within 30 days of screening 3. Pregnant women or breast-feeding women, or women with childbearing potential not using of combination of two effective contraception methods throughout study 4. Renal impairment with glomerular filtration rate \<15mL /min 5. Child-Pugh C hepatic impairment
Conditions Elevated Blood Pressure, Hypertension, O...
Phase NA
Enrollment 1700
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Public health priorities have shifted towards disease prevention, emphasising health promotion and lifestyle interventions to reduce disease burden. Despite global efforts, the prevalence of chronic diseases remains high, with lifestyle factors such as alcohol consumption, diet, smoking, obesity, and sedentary behaviour playing significant roles. In Singapore, suboptimal lifestyle behaviours are common, contributing to a high incidence of chronic conditions. Metabolic syndrome (MetS), linked to obesity, poses a growing societal burden due to its association with cardiovascular risks. Disparities exist in the delivery of lifestyle interventions among healthcare providers (HCPs), with many patients receiving inadequate guidance. Digital health coaching, incorporating wearable technology, offers promising solutions to bridge these gaps, providing personalised, real-time support and feedback to improve lifestyle behaviours and prevent disease progression. Challenges such as time constraints, lack of feedback, and limited support can be addressed through remote monitoring and tailored interventions, making scalable population-level interventions feasible.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Device: Smart watch — Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.
  • Behavioral: Dashboard with nudging system — Nudges will be sent to participants' smart watch/mobile application with messages that are designed to motivate them to lead a healthy lifestyle.
  • Device: Digital Health Coach (DHC) — Participants will be assigned to a DHC and the DHC will be providing them with remote health coaching assistance for a duration of 6 months, upon successful enrolment.

Primary Outcomes

  • Changes in physical activity level (Baseline, 6- and 12-month post study enrolment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-06
Completion: 2026-02
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1700 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alexandra Hospital
Collaborators: National University of Singapore
Contact Information
Study Contact:
Elya Elya
96505306
ah_activation@nuhs.edu.sg
Jacqueline Lau
96505306
ah_activation@nuhs.edu.sg
ACTIVATION Team
96505306
ah_activation@nuhs.edu.sg
Alexandra Hospital
Interventions
  • Device: Smart watch — Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.
  • Behavioral: Dashboard with nudging system — Nudges will be sent to participants' smart watch/mobile application with messages that are designed to motivate them to lead a healthy lifestyle.
  • Device: Digital Health Coach (DHC) — Participants will be assigned to a DHC and the DHC will be providing them with remote health coaching assistance for a duration of 6 months, upon successful enrolment.
Study Locations (1 sites)
Alexandra Hospital, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: * 21-75 years old * Patients who are at risk of any of the following: 1. Elevated blood pressure 2. Overweight (BMI\>=23kg/m2) 3. Pre-diabetes, OR * Patients who have one or more of the following (HOLD) conditions: 1. Hypertension 2. Obesity (BMI\>=27.5kg/m2) 3. HyperLipidemia 4. Type 2 Diabetes Mellitus * Patients who own a smartphone * Patients who are willing to wear a smartwatch during the intervention period. Exclusion Criteria: * Patients who have a medical condition that prevented participation in physical activity * Patients who have current diagnosis or history of eating disorder, depression * Patients who are currently pregnant or planning to become pregnant in the next 6 months * Patients who are currently participating in a weight loss programme (commercial, medically supervised, or research study) * Patients who are on weight loss medications (over-the-counter or prescription) * Patients who are not mentally-, physically- or technologically-capable * Patients who is unable to provide informed consent.
Conditions Type 2 Diabetes
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This project will compare medical nutrition therapy personalized by continuous glucose monitor (CGM) feedback to control interventions in participants with type 2 diabetes mellitus (T2DM).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Unblinded CGM/Nutrition Therapy — Personalized nutrition counseling based on CGM data
  • Behavioral: Blinded CGM/Nutrition Therapy — Standard nutrition education which does not incorporate CGM data
  • Behavioral: Unblinded CGM/No Nutrition Therapy — CGM and general diabetes education (no nutrition education)
  • Behavioral: Blinded CGM/No Nutrition Therapy — General diabetes education (no nutrition education)

Primary Outcomes

  • Hemoglobin A1c (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-14
Completion: 2027-09-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Minnesota
Principal Investigators:
  • Anne Bantle (PRINCIPAL_INVESTIGATOR) - University of Minnesota
Contact Information
Study Contact:
Anne Bantle
612-625-8673
bant0015@umn.edu
Anne Bantle
University of Minnesota
Interventions
  • Behavioral: Unblinded CGM/Nutrition Therapy — Personalized nutrition counseling based on CGM data
  • Behavioral: Blinded CGM/Nutrition Therapy — Standard nutrition education which does not incorporate CGM data
  • Behavioral: Unblinded CGM/No Nutrition Therapy — CGM and general diabetes education (no nutrition education)
  • Behavioral: Blinded CGM/No Nutrition Therapy — General diabetes education (no nutrition education)
Study Locations (1 sites)
University of Minnesota, Minneapolis, Minnesota 55455 United States
Eligibility Criteria
Inclusion Criteria: * at least 18 years of age * previous diagnosis of T2DM * HbA1c of 6.8-8.5% Exclusion Criteria: * type 1 diabetes mellitus * treatment with insulin, sulfonylurea, or meglitinide * use of nondiabetic medications that affect blood glucose control (such as corticosteroids) * BMI \<25 kg/m2 or \<23 kg/m2 for participants who self-identify as Asian * weight change \>5 pounds in the 3 months prior to study enrollment * estimated glomerular filtration rate \<60 ml/minute/1.73 m2 * pregnancy or immediate plans to become pregnant 8) breastfeeding 9) anemia (which would affect measurement of HbA1c) 10) changes to glucose lowering medications, including change in dose, in the 3 months prior to enrollment 11) presence of any disease that would make adherence to the protocol difficult."
Conditions Breast Cancer Risk, Breast Cancer Preven...
Phase Not Applicable
Enrollment 25000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn more about how genes impact the risk of breast cancer. Anyone 18 or older living in the US is eligible, and a diagnosis of cancer is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Genetic: Saliva sample — Saliva sample is sent via prepaid US Mail for DNA extraction
  • Other: Health Surveys — Health surveys are filled out online in the study portal.

Primary Outcomes

  • Genetic risk variants associated with breast cancer (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-04-15
Completion: 2028-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 25000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rutgers, The State University of New Jersey
Collaborators: Regeneron Pharmaceuticals
Principal Investigators:
  • Tara Matise, Ph.D. (PRINCIPAL_INVESTIGATOR) - Rutgers, The State University of New Jersey
Contact Information
Study Contact:
Tara Matise, Ph.D.
848-445-3125
rugcc@rutgers.edu
Steve Buyske, Ph.D.
848-445-7680
rugcc@rutgers.edu
Tara Matise, Ph.D.
848-445-3125
rugcc@rutgers.edu
Rutgers University
Interventions
  • Genetic: Saliva sample — Saliva sample is sent via prepaid US Mail for DNA extraction
  • Other: Health Surveys — Health surveys are filled out online in the study portal.
Study Locations (1 sites)
Rutgers University, Piscataway, New Jersey 08854 United States
Eligibility Criteria
Inclusion Criteria: * age 18 years or older * currently living in the United States * able to understand and follow written instructions in English * have access to the internet and a computer, laptop, tablet or smart phone * willing to provide written informed consent for participation * willing to provide DNA via a saliva sample using a collection kit mailed to the study participant's home * willing to complete a survey with questions about health related to the study of breast cancer. Exclusion Criteria: * Not able to meet or fulfill any of the inclusion criteria
Conditions Chronic Kidney Disease and Hypertension
Phase PHASE3
Enrollment 5000
Locations 771 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Baxdrostat/dapagliflozin — baxdrostat tablet dapagliflozin tablet
  • Drug: Placebo/dapagliflozin — dapagliflozin tablet placebo tablet

Primary Outcomes

  • To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death. (Up to 37 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-03-03
Completion: 2029-12-18
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: Baxdrostat/dapagliflozin — baxdrostat tablet dapagliflozin tablet
  • Drug: Placebo/dapagliflozin — dapagliflozin tablet placebo tablet
Study Locations (771 sites)
Research Site, Fairhope, Alabama 36532 United States
Research Site, Surprise, Arizona 85374 United States
Research Site, Tucson, Arizona 85741 United States
Research Site, Beverly Hills, California 90211 United States
Research Site, Canoga Park, California 91303 United States
Research Site, Concord, California 94520 United States
Research Site, Fremont, California 94538 United States
Research Site, Fullerton, California 92835 United States
Research Site, Inglewood, California 90301 United States
Research Site, Los Alamitos, California 90720 United States
Eligibility Criteria
Inclusion Criteria: 1. Participants of any sex and gender must be ≥ 18 years of age at the time of signing the informed consent. 2. Participants with (a) or (b): a) eGFR 30-59 mL/min/1.73 m² (local or central laboratory value) AND: * UACR ≥ 30 mg/g (3.39 mg/mmol) and \< 500 mg/g (56.5 mg/mmol) (central laboratory value only), or * UACR ≥ 500 mg/g (56.5 mg/mmol) and ≤ 5000 mg/g (565 mg/mmol) (local or central laboratory value), or * UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local laboratory value only). (b) eGFR 60-75 mL/min/1.73 m² (local or central laboratory value) AND: * UACR ≥ 500 mg/g (56.5 mg/mmol) ) and ≤ 5000 mg/g (565 mg/mmol) (local or central laboratory value), or * UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local laboratory value only) 3. \[obsolete\] 4. Participants with history of HTN and a SBP ≥ 130 mmHg (the most recent value within 4 weeks prior to screening or at the Screening Visit) and ≥ 120 mmHg at the Randomisation Visit. 5. Stable and maximum tolerated dose of an ACEi or an ARB (not both) for at least 4 weeks prior to Screening Visit. 6. Participants with: 1. Serum or plasma potassium ≥ 3.0 and ≤ 4.8 mmol/L if eGFR ≥ 45 mL/min/1.73 m2 (local or central laboratory values) 2. Serum or plasma potassium ≥ 3.0 and ≤ 4.5 mmol/L if eGFR \< 45 mL/min/1.73 m2 (local or central laboratory values) Exclusion Criteria: 1. Systolic blood pressure \> 180 mmHg, or diastolic BP \> 110 mmHg at screening. 2. Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months at screening. 3. Serum sodium \< 135 mmol/L (central or local laboratory values obtained within 4 weeks prior to screening or at the Screening Visit). 4\. Participants with T1DM will be excluded, except: 1. For US only: patients with T1DM treated with SGLT2i for at least 4 months, without DKA during that period, and who have experience with ketone monitoring are eligible for inclusion. 2. For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months, without DKA during the period of dapagliflozin treatment are eligible for inclusion. 5 Uncontrolled T2DM with HbA1c \> 10.5% (\> 91 mmol/mol) (central or local laboratory values obtained within 3 months prior to screening or at the Screening Visit). 6 New York Heart Association functional HF class IV at screening. 7 Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening heart failure within previous 3 months prior to randomisation. 8 Documented history of adrenal insufficiency. 9 Any dialysis (including for acute kidney injury) within 3 months prior to Screening Visit. 10 Any acute kidney injury within 3 months prior to the Screening Visit. 11 History of organ transplant or bone marrow transplant, or planned organ transplant within 6 months following randomisation (including kidney transplant). 12 Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months prior to Visit 1).